- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02733744
Fecal Microbiota Transplantation After HSCT
A Pilot Study to Determine the Feasibility of Fecal MicrobiotaTransplantation (FMT) in Hematopoietic Stem Cell Transplantation (HSCT) Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The microbiome (spectrum of bacteria in a patient's gut) is thought to play a role in helping to shape one's immune system given its direct contact with normal cells in our intestine. Recent studies have suggested that a microbiome with very few bacteria (low diversity) seems to be bad for health and a high-diversity microbiome (many different species) appears to be good. This appears to be true even for patients after HSCT where low diversity microbiome status has correlated with infections, GVHD and overall survival.
Fecal microbiota transplantation (FMT) is routinely performed for an infection caused by Clostridium difficile but is not yet approved by the FDA as a treatment for any disease. FMT restores a high diversity microbiome. It is hoped that through FMT, overall outcomes after HSCT can potentially be improved.
FMT will be performed in the first 3 weeks after recovery of white blood cells after HSCT. The source of FMT will be from healthy 3rd party donors. FMT will be performed through the ingestion of 30 capsules over 2 consecutive days.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women ≥ 18 and ≤ 65 years old
- Patients designated to undergo myeloablative or intermediate intensity allogeneic peripheral blood or bone marrow hematopoietic cell transplantation. Consent will be obtained prior to admission for HSCT. Patients receiving any donor source of stem cells are eligible. Eligible conditioning regimens are those defined as myeloablative by Consensus Criteria (Bacigalupo 2009) as well as the combination of fludarabine with melphalan (100-140 mg/mg2)
- Any Graft-vs-Host disease (GVHD) prophylaxis regimen is allowed.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A)
Patients with adequate physical function as measured by
- Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening fraction >25%.
Hepatic:
- Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Alkaline Phosphatase < 5 x Upper Limit of Institutional Normal Range (ULN).
- Renal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) ≥ 40millileters/min/1.73m2.
- Pulmonary: Diffusing lung capacity for carbon monoxide (DLCO) (corrected for hemoglobin), Forced expiratory volume in 1 second (FEV1) and Forced vital capacity (FVC) ≥ 50% predicted.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT.
- Ability to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool.
- Ability to swallow oral medications.
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received a prior autologous hematopoietic stem cell transplant.)
- Participants who are receiving any other investigational agents.
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
- Patients with history of primary idiopathic myelofibrosis or any severe marrow fibrosis.
- Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.
- Delayed gastric emptying syndrome
- Known chronic aspiration
- Patients with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
- Pregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation.
- HIV-positive participants are ineligible.
- Participants who are unable to swallow pills.
- Participants with end-stage liver disease (cirrhosis)
- Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis)
- Participants with inflammatory bowel disease (e.g., ulcerative colitis, Crohn's)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fecal Microbiota Transplant
Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards. Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water. |
FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility measured by number of participants able to ingest 15 FMT capsules over a 2-day period
Time Frame: 2 days
|
Number of participants able to ingest 15 FMT capsules over a 2 day period.
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 2 years
|
2 years
|
|
Overall Survival
Time Frame: 2 years
|
2 years
|
|
Cumulative Incidence Of aGVHD
Time Frame: 2 years
|
2 years
|
|
Non-Relapse Mortality Rate
Time Frame: 2 years
|
2 years
|
|
Number of participants with treatment-related adverse events
Time Frame: 1 year
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yi-Bin Chen, MD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 16-023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Marrow Transplantation
-
National Center for Complementary and Integrative...National Cancer Institute (NCI)CompletedStem Cell Transplantation | Bone Marrow TransplantationUnited States
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States
-
GlaxoSmithKlineCompletedBone Marrow TransplantationUnited States
-
University of PittsburghRecruitingBone Marrow Transplantation | Solid Organ TransplantationUnited States
-
Hospital Israelita Albert EinsteinRecruitingImpact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT (Yoga)Bone Marrow Transplantation | Hematopoietic Stem Cell TransplantationBrazil
-
National Institute of Allergy and Infectious Diseases...RecruitingBone Marrow TransplantationUnited States
-
Ming-Yuan ChihCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedBone Marrow Transplantation
-
University of California, San FranciscoCompleted
-
Shaymaa Mohammed El-AwadyRecruitingAllogenic Bone Marrow TransplantationEgypt
Clinical Trials on Fecal Microbiota Transplantation (FMT)
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAllogeneic Hematopoietic Stem CellUnited States
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
The Second Hospital of Nanjing Medical UniversityFuzhou General HospitalUnknown
-
University Hospital of North NorwayOslo University Hospital; Haukeland University Hospital; Sorlandet Hospital HF; Alesund HospitalActive, not recruitingIrritable Bowel SyndromeNorway
-
Susy HotaSinai Health System, Ontario, Canada; University of Toronto, Ontario, Canada; The Toronto Invasive Bacterial Diseases Network, Ontario, Canada and other collaboratorsSuspended
-
Brigham and Women's HospitalIcahn School of Medicine at Mount Sinai; The Miriam Hospital; Indiana UniversityCompletedInflammatory Bowel Diseases | Clostridium Difficile InfectionUnited States
-
Children's Hospital Los AngelesCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingIrritable Bowel SyndromeItaly
-
LifespanUnknownNonalcoholic Fatty Liver DiseaseUnited States
-
University of CologneUnknownClostridium InfectionsGermany